7/31/2019 Fibrocystic Changes

1/335

Fibrocystic changes

a)is the most common breast disorder in women

b)is due to abnormal response to ovarian hormones

c)is associated with in-situ carcinoma

d)has high risk of developing breast cancer

e)is also known as fibroadenoma

2.

Endo

7/31/2019 Fibrocystic Changes

2/335

metri

al

cance

7/31/2019 Fibrocystic Changes

3/335

r

isa)associ

7/31/2019 Fibrocystic Changes

4/335

atedwithuse

7/31/2019 Fibrocystic Changes

5/335

ofintrauteri

7/31/2019 Fibrocystic Changes

6/335

necontracep

7/31/2019 Fibrocystic Changes

7/335

tivedevice

7/31/2019 Fibrocystic Changes

8/335

b)associated

7/31/2019 Fibrocystic Changes

9/335

withexcess

7/31/2019 Fibrocystic Changes

10/335

estrogenc)ob

7/31/2019 Fibrocystic Changes

11/335

esityas arisk

7/31/2019 Fibrocystic Changes

12/335

factord)cle

7/31/2019 Fibrocystic Changes

13/335

arcellCA is

7/31/2019 Fibrocystic Changes

14/335

themostcom

7/31/2019 Fibrocystic Changes

15/335

mone)associa

7/31/2019 Fibrocystic Changes

16/335

tedwithHPV

7/31/2019 Fibrocystic Changes

17/335

infection

7/31/2019 Fibrocystic Changes

18/335

3.Inthearea

7/31/2019 Fibrocystic Changes

19/335

ofmolecular

7/31/2019 Fibrocystic Changes

20/335

pathologyand

7/31/2019 Fibrocystic Changes

21/335

moleculardiag

7/31/2019 Fibrocystic Changes

22/335

nosis,

7/31/2019 Fibrocystic Changes

23/335

a)Thedete

7/31/2019 Fibrocystic Changes

24/335

ctionofmon

7/31/2019 Fibrocystic Changes

25/335

oclonalityis

7/31/2019 Fibrocystic Changes

26/335

essentialin

7/31/2019 Fibrocystic Changes

27/335

diagnosing

7/31/2019 Fibrocystic Changes

28/335

biopsysam

7/31/2019 Fibrocystic Changes

29/335

plesof

7/31/2019 Fibrocystic Changes

30/335

breastcanc

7/31/2019 Fibrocystic Changes

31/335

er.b)Micros

7/31/2019 Fibrocystic Changes

32/335

omalinstability

7/31/2019 Fibrocystic Changes

33/335

arehelpful in

7/31/2019 Fibrocystic Changes

34/335

diagnosing

7/31/2019 Fibrocystic Changes

35/335

HNPCCc)Th

7/31/2019 Fibrocystic Changes

36/335

edetection

7/31/2019 Fibrocystic Changes

37/335

ofmonoclon

7/31/2019 Fibrocystic Changes

38/335

alityisesse

7/31/2019 Fibrocystic Changes

39/335

ntialindiag

7/31/2019 Fibrocystic Changes

40/335

nosingbiops

7/31/2019 Fibrocystic Changes

41/335

ysam

7/31/2019 Fibrocystic Changes

42/335

plesof

7/31/2019 Fibrocystic Changes

43/335

lymphomas

7/31/2019 Fibrocystic Changes

44/335

d)HER2-neu

7/31/2019 Fibrocystic Changes

45/335

genedetection

7/31/2019 Fibrocystic Changes

46/335

byFISHtest

7/31/2019 Fibrocystic Changes

47/335

isusedto

7/31/2019 Fibrocystic Changes

48/335

diagnoseinher

7/31/2019 Fibrocystic Changes

49/335

itedbreast

7/31/2019 Fibrocystic Changes

50/335

cancer

7/31/2019 Fibrocystic Changes

51/335

e)FAP iscaus

7/31/2019 Fibrocystic Changes

52/335

edbymuta

7/31/2019 Fibrocystic Changes

53/335

tionsinthe

7/31/2019 Fibrocystic Changes

54/335

mis-match

7/31/2019 Fibrocystic Changes

55/335

repair

7/31/2019 Fibrocystic Changes

56/335

genes.

7/31/2019 Fibrocystic Changes

57/335

4.Gran

7/31/2019 Fibrocystic Changes

58/335

ulomas

7/31/2019 Fibrocystic Changes

59/335

a)aremainly

7/31/2019 Fibrocystic Changes

60/335

composeof

7/31/2019 Fibrocystic Changes

61/335

macrophages,

7/31/2019 Fibrocystic Changes

62/335

epitheloidcells

7/31/2019 Fibrocystic Changes

63/335

andlymphocyt

7/31/2019 Fibrocystic Changes

64/335

esb)arealwa

7/31/2019 Fibrocystic Changes

65/335

yscaused

7/31/2019 Fibrocystic Changes

66/335

byinfections

7/31/2019 Fibrocystic Changes

67/335

c)aremediated

7/31/2019 Fibrocystic Changes

68/335

byCD4+T

7/31/2019 Fibrocystic Changes

69/335

lymphocytes

7/31/2019 Fibrocystic Changes

70/335

d)aremediated

7/31/2019 Fibrocystic Changes

71/335

byIL-2and

7/31/2019 Fibrocystic Changes

72/335

alphaIFN

7/31/2019 Fibrocystic Changes

73/335

e)alwayscont

7/31/2019 Fibrocystic Changes

74/335

ainareaof

7/31/2019 Fibrocystic Changes

75/335

central

7/31/2019 Fibrocystic Changes

76/335

necrosis

7/31/2019 Fibrocystic Changes

77/335

5.Thesequ

7/31/2019 Fibrocystic Changes

78/335

enceofmeta

7/31/2019 Fibrocystic Changes

79/335

plasia-dyspl

7/31/2019 Fibrocystic Changes

80/335

asia-neoplasia

7/31/2019 Fibrocystic Changes

81/335

occurs inthe

7/31/2019 Fibrocystic Changes

82/335

neogenesis of

7/31/2019 Fibrocystic Changes

83/335

a)squamous

7/31/2019 Fibrocystic Changes

84/335

cellcarcinom

7/31/2019 Fibrocystic Changes

85/335

abladder

7/31/2019 Fibrocystic Changes

86/335

b)carcinoid of

7/31/2019 Fibrocystic Changes

87/335

thesmall

7/31/2019 Fibrocystic Changes

88/335

intestine

7/31/2019 Fibrocystic Changes

89/335

c)adenocarcin

7/31/2019 Fibrocystic Changes

90/335

omaofthe

7/31/2019 Fibrocystic Changes

91/335

Barret'soesp

7/31/2019 Fibrocystic Changes

92/335

hagus

7/31/2019 Fibrocystic Changes

93/335

d)squamous

7/31/2019 Fibrocystic Changes

94/335

cellcarcinom

7/31/2019 Fibrocystic Changes

95/335

a ofthelungs

7/31/2019 Fibrocystic Changes

96/335

e)malignant

7/31/2019 Fibrocystic Changes

97/335

lymphoma

7/31/2019 Fibrocystic Changes

98/335

6. Inacute

7/31/2019 Fibrocystic Changes

99/335

inflammation

7/31/2019 Fibrocystic Changes

100/335

a)decreased

7/31/2019 Fibrocystic Changes

101/335

bloodflow

7/31/2019 Fibrocystic Changes

102/335

toaffected

7/31/2019 Fibrocystic Changes

103/335

partb)increas

7/31/2019 Fibrocystic Changes

104/335

edvascular

7/31/2019 Fibrocystic Changes

105/335

permeability to

7/31/2019 Fibrocystic Changes

106/335

proteins

7/31/2019 Fibrocystic Changes

107/335

c)isassociate

7/31/2019 Fibrocystic Changes

108/335

dwithlocal

7/31/2019 Fibrocystic Changes

109/335

5hydroxytr

7/31/2019 Fibrocystic Changes

110/335

ytamine

7/31/2019 Fibrocystic Changes

111/335

release

7/31/2019 Fibrocystic Changes

112/335

d)causedby

7/31/2019 Fibrocystic Changes

113/335

mechanical

7/31/2019 Fibrocystic Changes

114/335

trauma

7/31/2019 Fibrocystic Changes

115/335

e)amanifesta

7/31/2019 Fibrocystic Changes

116/335

tionofthe

7/31/2019 Fibrocystic Changes

117/335

ability ofnorm

7/31/2019 Fibrocystic Changes

118/335

altissues to

7/31/2019 Fibrocystic Changes

119/335

respondto

7/31/2019 Fibrocystic Changes

120/335

damage

7/31/2019 Fibrocystic Changes

121/335

7.Regarding

7/31/2019 Fibrocystic Changes

122/335

Osteoarthritis

7/31/2019 Fibrocystic Changes

123/335

a)cartilage

7/31/2019 Fibrocystic Changes

124/335

fibrillation

7/31/2019 Fibrocystic Changes

125/335

b)pannus

7/31/2019 Fibrocystic Changes

126/335

formation

7/31/2019 Fibrocystic Changes

127/335

c)eburnation

7/31/2019 Fibrocystic Changes

128/335

ofbone

7/31/2019 Fibrocystic Changes

129/335

d)herberde

7/31/2019 Fibrocystic Changes

130/335

n'snodes

7/31/2019 Fibrocystic Changes

131/335

e)osteophyte

7/31/2019 Fibrocystic Changes

132/335

formation

7/31/2019 Fibrocystic Changes

133/335

8.Macr

7/31/2019 Fibrocystic Changes

134/335

ophages

7/31/2019 Fibrocystic Changes

135/335

a)play arole

7/31/2019 Fibrocystic Changes

136/335

ingraft

7/31/2019 Fibrocystic Changes

137/335

rejection

7/31/2019 Fibrocystic Changes

138/335

b)areinvolved

7/31/2019 Fibrocystic Changes

139/335

inantigen

7/31/2019 Fibrocystic Changes

140/335

recognition

7/31/2019 Fibrocystic Changes

141/335

c)Havemem

7/31/2019 Fibrocystic Changes

142/335

branerece

7/31/2019 Fibrocystic Changes

143/335

ptorsforFc

7/31/2019 Fibrocystic Changes

144/335

fragmentof

7/31/2019 Fibrocystic Changes

145/335

antibodiesd)Is

7/31/2019 Fibrocystic Changes

146/335

involvedin

7/31/2019 Fibrocystic Changes

147/335

type4hype

7/31/2019 Fibrocystic Changes

148/335

rsensitivity

7/31/2019 Fibrocystic Changes

149/335

e)Haveno

7/31/2019 Fibrocystic Changes

150/335

phagocytic

7/31/2019 Fibrocystic Changes

151/335

properties

7/31/2019 Fibrocystic Changes

152/335

9.Lowgrad

7/31/2019 Fibrocystic Changes

153/335

elymp

7/31/2019 Fibrocystic Changes

154/335

homas:

7/31/2019 Fibrocystic Changes

155/335

a)Incurable

7/31/2019 Fibrocystic Changes

156/335

b)monoclonal

7/31/2019 Fibrocystic Changes

157/335

proliferation of

7/31/2019 Fibrocystic Changes

158/335

largelymp

7/31/2019 Fibrocystic Changes

159/335

hoidcells

7/31/2019 Fibrocystic Changes

160/335

c)clinically

7/31/2019 Fibrocystic Changes

161/335

aggressive

7/31/2019 Fibrocystic Changes

162/335

10.11.Whic

7/31/2019 Fibrocystic Changes

163/335

h ofthefollo

7/31/2019 Fibrocystic Changes

164/335

winghelpsin

7/31/2019 Fibrocystic Changes

165/335

thegrading of

7/31/2019 Fibrocystic Changes

166/335

atumor?

7/31/2019 Fibrocystic Changes

167/335

a)thepresence

7/31/2019 Fibrocystic Changes

168/335

orabsence

7/31/2019 Fibrocystic Changes

169/335

ofmetastase

7/31/2019 Fibrocystic Changes

170/335

s inthelymp

7/31/2019 Fibrocystic Changes

171/335

hnode

7/31/2019 Fibrocystic Changes

172/335

b)thedegree of

7/31/2019 Fibrocystic Changes

173/335

differentiation

7/31/2019 Fibrocystic Changes

174/335

c)thepresence

7/31/2019 Fibrocystic Changes

175/335

oftumor

7/31/2019 Fibrocystic Changes

176/335

necrosis

7/31/2019 Fibrocystic Changes

177/335

d)mitotic

7/31/2019 Fibrocystic Changes

178/335

activity

7/31/2019 Fibrocystic Changes

179/335

e)thepresence

7/31/2019 Fibrocystic Changes

180/335

ofcellsin

7/31/2019 Fibrocystic Changes

181/335

thevascular

7/31/2019 Fibrocystic Changes

182/335

spaces

7/31/2019 Fibrocystic Changes

183/335

12.Successfu

7/31/2019 Fibrocystic Changes

184/335

lhealing of

7/31/2019 Fibrocystic Changes

185/335

longbones

7/31/2019 Fibrocystic Changes

186/335

dependsupon

7/31/2019 Fibrocystic Changes

187/335

:a)appositi

7/31/2019 Fibrocystic Changes

188/335

on ofthefrag

7/31/2019 Fibrocystic Changes

189/335

7/31/2019 Fibrocystic Changes

190/335

rgicalremoval of

7/31/2019 Fibrocystic Changes

191/335

thehematom

7/31/2019 Fibrocystic Changes

192/335

ac)Free

7/31/2019 Fibrocystic Changes

193/335

mobility ofthe

7/31/2019 Fibrocystic Changes

194/335

limbd)The

7/31/2019 Fibrocystic Changes

195/335

absenceof

7/31/2019 Fibrocystic Changes

196/335

infectione)Ele

7/31/2019 Fibrocystic Changes

197/335

vation of

7/31/2019 Fibrocystic Changes

198/335

thelimb

7/31/2019 Fibrocystic Changes

199/335

13.Small cell

7/31/2019 Fibrocystic Changes

200/335

carcinoma of

7/31/2019 Fibrocystic Changes

201/335

thelungis:

7/31/2019 Fibrocystic Changes

202/335

a.Isnotasso

7/31/2019 Fibrocystic Changes

203/335

ciatedwith

7/31/2019 Fibrocystic Changes

204/335

cigarettesmok

7/31/2019 Fibrocystic Changes

205/335

ing.b.Isusual

7/31/2019 Fibrocystic Changes

206/335

lyfound in

7/31/2019 Fibrocystic Changes

207/335

theperiphery

7/31/2019 Fibrocystic Changes

208/335

ofthelung.

7/31/2019 Fibrocystic Changes

209/335

c.Ismorecom

7/31/2019 Fibrocystic Changes

210/335

moninwom

7/31/2019 Fibrocystic Changes

211/335

enthanmen.

7/31/2019 Fibrocystic Changes

212/335

d.Oftenprod

7/31/2019 Fibrocystic Changes

213/335

ucesectopic

7/31/2019 Fibrocystic Changes

214/335

hormonese.Ha

7/31/2019 Fibrocystic Changes

215/335

s apoorprog

7/31/2019 Fibrocystic Changes

216/335

7/31/2019 Fibrocystic Changes

217/335

14.Adultrespi

7/31/2019 Fibrocystic Changes

218/335

ratorydistr

7/31/2019 Fibrocystic Changes

219/335

esssynd

7/31/2019 Fibrocystic Changes

220/335

rome:

7/31/2019 Fibrocystic Changes

221/335

a)pulmonary

7/31/2019 Fibrocystic Changes

222/335

edema isa

7/31/2019 Fibrocystic Changes

223/335

feature

7/31/2019 Fibrocystic Changes

224/335

b)hyalinemem

7/31/2019 Fibrocystic Changes

225/335

brane ispres

7/31/2019 Fibrocystic Changes

226/335

entin

7/31/2019 Fibrocystic Changes

227/335

alveoli

7/31/2019 Fibrocystic Changes

228/335

c)has ahigh

7/31/2019 Fibrocystic Changes

229/335

mortality

7/31/2019 Fibrocystic Changes

230/335

d)associated

7/31/2019 Fibrocystic Changes

231/335

7/31/2019 Fibrocystic Changes

232/335

pancreatitis

7/31/2019 Fibrocystic Changes

233/335

e)canoccu

7/31/2019 Fibrocystic Changes

234/335

rfollowing

7/31/2019 Fibrocystic Changes

235/335

diffusealveo

7/31/2019 Fibrocystic Changes

236/335

larinjury15.

7/31/2019 Fibrocystic Changes

237/335

16.Fallin

7/31/2019 Fibrocystic Changes

238/335

blood pHfrom

7/31/2019 Fibrocystic Changes

239/335

7.40to7.10

7/31/2019 Fibrocystic Changes

240/335

a)represents

7/31/2019 Fibrocystic Changes

241/335

anapproxim

7/31/2019 Fibrocystic Changes

242/335

atedoubling

7/31/2019 Fibrocystic Changes

243/335

ofH+conc

7/31/2019 Fibrocystic Changes

244/335

entrationb)ch

7/31/2019 Fibrocystic Changes

245/335

aracteristically

7/31/2019 Fibrocystic Changes

246/335

causedby

7/31/2019 Fibrocystic Changes

247/335

persistentvomit

7/31/2019 Fibrocystic Changes

248/335

ingc)charact

7/31/2019 Fibrocystic Changes

249/335

eristicallycaus

7/31/2019 Fibrocystic Changes

250/335

edbyhype

7/31/2019 Fibrocystic Changes

251/335

rventilationd)c

7/31/2019 Fibrocystic Changes

252/335

anbeacco

7/31/2019 Fibrocystic Changes

253/335

mpaniedby

7/31/2019 Fibrocystic Changes

254/335

elevatedseru

7/31/2019 Fibrocystic Changes

255/335

mpota

7/31/2019 Fibrocystic Changes

256/335

ssium

7/31/2019 Fibrocystic Changes

257/335

e)isincompat

7/31/2019 Fibrocystic Changes

258/335

iblewithlife

7/31/2019 Fibrocystic Changes

259/335

17.Whatof

7/31/2019 Fibrocystic Changes

260/335

thefollowing

7/31/2019 Fibrocystic Changes

261/335

causeseleva

7/31/2019 Fibrocystic Changes

262/335

tedtotalCSF

7/31/2019 Fibrocystic Changes

263/335

protein:

7/31/2019 Fibrocystic Changes

264/335

a)CNS

7/31/2019 Fibrocystic Changes

265/335

tumour

7/31/2019 Fibrocystic Changes

266/335

b)CVA

7/31/2019 Fibrocystic Changes

267/335

c)Epilepsy

7/31/2019 Fibrocystic Changes

268/335

d)Viral

7/31/2019 Fibrocystic Changes

269/335

meningitis

7/31/2019 Fibrocystic Changes

270/335

e)CNS

7/31/2019 Fibrocystic Changes

271/335

trauma

7/31/2019 Fibrocystic Changes

272/335

18. HPylori

7/31/2019 Fibrocystic Changes

273/335

a)associated

7/31/2019 Fibrocystic Changes

274/335

withgastric

7/31/2019 Fibrocystic Changes

275/335

carcinoma

7/31/2019 Fibrocystic Changes

276/335

andlymphom

7/31/2019 Fibrocystic Changes

277/335

ab)causes

7/31/2019 Fibrocystic Changes

278/335

achronic

7/31/2019 Fibrocystic Changes

279/335

lymphoid

7/31/2019 Fibrocystic Changes

280/335

infiltration

7/31/2019 Fibrocystic Changes

281/335

c)isaurea

-prod

7/31/2019 Fibrocystic Changes

282/335

ucingorganism

7/31/2019 Fibrocystic Changes

283/335

d)isusually

7/31/2019 Fibrocystic Changes

284/335

found inarea

7/31/2019 Fibrocystic Changes

285/335

s ofintestinal

7/31/2019 Fibrocystic Changes

286/335

metaplasia

7/31/2019 Fibrocystic Changes

287/335

e)causesa

7/31/2019 Fibrocystic Changes

288/335

chronicgastr

7/31/2019 Fibrocystic Changes

289/335

itisbyinvad

7/31/2019 Fibrocystic Changes

290/335

ingthemuc

7/31/2019 Fibrocystic Changes

291/335

osalepithelium

7/31/2019 Fibrocystic Changes

292/335

19.Pseudom

7/31/2019 Fibrocystic Changes

293/335

embranous

7/31/2019 Fibrocystic Changes

294/335

Colitis

7/31/2019 Fibrocystic Changes

295/335

a)causedby

7/31/2019 Fibrocystic Changes

296/335

clostridiumdiffici

7/31/2019 Fibrocystic Changes

297/335

letoxin

7/31/2019 Fibrocystic Changes

298/335

b)ispresent

7/31/2019 Fibrocystic Changes

299/335

inimmunos

7/31/2019 Fibrocystic Changes

300/335

uppressed

7/31/2019 Fibrocystic Changes

301/335

individualsc)toxi

7/31/2019 Fibrocystic Changes

302/335

nmediated

7/31/2019 Fibrocystic Changes

303/335

injurycauses

7/31/2019 Fibrocystic Changes

304/335

epithelialshed

7/31/2019 Fibrocystic Changes

305/335

dingandnecr

7/31/2019 Fibrocystic Changes

306/335

osisd)pseudo

7/31/2019 Fibrocystic Changes

307/335

membranes

7/31/2019 Fibrocystic Changes

308/335

presentby

7/31/2019 Fibrocystic Changes

309/335

desloughing of

7/31/2019 Fibrocystic Changes

310/335

epitheliume)as

7/31/2019 Fibrocystic Changes

311/335

sociatedwith

7/31/2019 Fibrocystic Changes

312/335

antibioticuse

7/31/2019 Fibrocystic Changes

313/335

20.Concernin

7/31/2019 Fibrocystic Changes

314/335

gSLEa)cir

7/31/2019 Fibrocystic Changes

315/335

culatingimm

7/31/2019 Fibrocystic Changes

316/335

unecomplexe

7/31/2019 Fibrocystic Changes

317/335

sresponsib

7/31/2019 Fibrocystic Changes

318/335

le forglomerulo

7/31/2019 Fibrocystic Changes

319/335

nephritisb)ab

7/31/2019 Fibrocystic Changes

320/335

soluteincre

7/31/2019 Fibrocystic Changes

321/335

asein Tsupp

7/31/2019 Fibrocystic Changes

322/335

ressorcells

7/31/2019 Fibrocystic Changes

323/335

c)renalbiops

7/31/2019 Fibrocystic Changes

324/335

yseldom

7/31/2019 Fibrocystic Changes

325/335

requiredfor

7/31/2019 Fibrocystic Changes

326/335

directingthera

7/31/2019 Fibrocystic Changes

327/335

pyd)renal

7/31/2019 Fibrocystic Changes

328/335

biopsyinclu

7/31/2019 Fibrocystic Changes

329/335

desactive

7/31/2019 Fibrocystic Changes

330/335

diffuseprolif

7/31/2019 Fibrocystic Changes

331/335

eratingglom

7/31/2019 Fibrocystic Changes

332/335

erulonephritis

7/31/2019 Fibrocystic Changes

333/335

e)ITPcan

7/31/2019 Fibrocystic Changes

334/335

beinitialmani

7/31/2019 Fibrocystic Changes

335/335

festation